한국어
Quantus

GC

005250 · KOSPI
₩9,900+0.51%
2026-09-04 close

GC last closed at ₩9,900 (+0.51%) on 2026-09-04. Listed on KOSPI; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

B-
Overall: 건강관리 166/291 · top 57%
Factor composite · relative position in sector

PER 19.92 · PBR 0.48 — own-history percentile 56/100 · 100/100

Open self-history band
PER56/100
PBR100/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart1987: 20원19871988: 22원1989: 25원1990: 11원19901991: 24원1992: 21원1993: 25원1994: 23원1995: 29원19951996: 32원1997: 22원1998: 32원1999: 47원2000: 68원20002001: 136원2002: 114원2003: 136원2004: 114원2005: 136원20052006: 136원2007: 136원2008: 182원2009: 182원2010: 227원20102011: 295원2012: 250원2013: 450원2014: 250원2015: 300원20152016: 300원2017: 300원2018: 300원2019: 250원2020: 325원20202021: 500원2022: 400원2023: 300원2024: 300원2025: 500원500원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
A+
Growth
B+
Yield
A
Safety
B-
Reference indicatorView observed cut rates

Paid 39 consecutive years · Raised 1 consecutive years · Yield 5.05% (based on 2025 payment of 500원) · 3-year growth +7.7%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 1.64
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
1.64
Beneish M-Score
-2.41

No statistical flag

Sloan accrual
3.11%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROAPass
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityWarning

OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 57% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 3 of 287, share 3.5%.

3 / 2873.5%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
6.6%
Interest coverage
2.2x
Return on equity (ROE)
2.4%

Operating margin −5pp

Interest coverage risk
Interest coverageBase 2.2x adverse case 0.5x
Return on equity (ROE)Base 2.4% adverse case -3.2%

Revenue −15%

Tolerable
Interest coverageBase 2.2x adverse case 1.9x
Return on equity (ROE)Base 2.4% adverse case 5.7%

Interest rate +2pp

Interest coverage risk
Interest coverageBase 2.2x adverse case 1.2x
Return on equity (ROE)Base 2.4% adverse case 2.5%

Interest coverage limit

Current margin 3.6pp

Interest coverage limit at an operating margin of 3%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-18

Suppliers disclosed by the company in its 2026-03-18 annual report.

Purchase amount

KRW 100m
  1. Capacity
    KRW 161.3B

Suppliers without disclosed amount

PlasmaBloodCentersAmericaTIGHBIGKRC

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 허일섭45.64%2026-06-15 · 증감 +0.33%p
  • 국민연금공단5.94%2026-04-01 · 증감 -1.02%p

Connections

AI-extracted related companies · for reference

Customers
WHO
🔗 See in the full market map →

Recent filings

GC's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About GC
What technical signals does GC (005250) have?
GC current technical signals: no active technical signal.
Is GC a cup-and-handle pattern?
No. GC has no valid cup-and-handle signal right now.
What are GC's financials and valuation?
GC's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy